within Pharmacolibrary.Drugs.ATC.S;

model S03BA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 3.5e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.00062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019666666666666666,
    Tlag           = 600,            
    Vdp             = 0.00047,
    k12             = 3.3055555555555558e-06,
    k21             = 3.3055555555555558e-06
    
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Prednisolone</td></tr><tr><td>ATC code:</td><td>S03BA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.62</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.18</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Prednisolone is a synthetic glucocorticoid drug with anti-inflammatory and immunosuppressive properties. It is widely used for the treatment of various inflammatory and autoimmune conditions, such as allergies, asthma, rheumatoid arthritis, and certain eye disorders. It is an approved medication and is still used clinically today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult subjects after oral administration of prednisolone.</p><h4>References</h4><ol><li><p>de Truchis, C, et al., &amp; Boyer, O (2023). Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant. <i>British journal of clinical pharmacology</i> 89(5) 1532–1540. DOI:<a href=\"https://doi.org/10.1111/bcp.15610\">10.1111/bcp.15610</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36510685/\">https://pubmed.ncbi.nlm.nih.gov/36510685</a></p></li><li><p>Petersen, KB, et al., &amp; Schmiegelow, K (2003). Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. <i>Cancer chemotherapy and pharmacology</i> 51(6) 465–473. DOI:<a href=\"https://doi.org/10.1007/s00280-003-0602-3\">10.1007/s00280-003-0602-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12698270/\">https://pubmed.ncbi.nlm.nih.gov/12698270</a></p></li><li><p>Yoshida, K, et al., &amp; Chanu, P (2021). Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. <i>Journal of clinical pharmacology</i> 61(12) 1579–1591. DOI:<a href=\"https://doi.org/10.1002/jcph.1942\">10.1002/jcph.1942</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34273118/\">https://pubmed.ncbi.nlm.nih.gov/34273118</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end S03BA02;
